Veraxa Biotech AG - Post de-SPAC VRXA
NASDAQ VRXA
$1.11 -0.04 (-3.48%)
At close: Nov 13, 2026 · 4:00 PM EST

Veraxa Biotech AG - Post de-SPAC (VRXA) Ending Cash Balance (2024 - 2025)

Updated

Analysis

Veraxa Biotech AG - Post de-SPAC (VRXA) Ending Cash Balance (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Ending Cash Balance (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 4.89 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 16.91 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 10.77 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 9.65 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 7.94 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 6.44 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 1.88 Bn
10 Veraxa Biotech AG - Post de-SPAC 16.07 Mn 12.50 Mn - 2.04 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 2.04 Mn
Dec 31, 2024 5.94 Mn
API Access

Veraxa Biotech AG - Post de-SPAC Ending Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ending-cash-balance&ticker=VRXA&period=max&api_key=YOUR_API_KEY